We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+13.73%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$178M
AUM Growth
+$74.8M
Cap. Flow
+$62M
Cap. Flow %
34.75%
Top 10 Hldgs %
63.3%
Holding
53
New
10
Increased
20
Reduced
12
Closed
3

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.4M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$4.04M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.09M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.96M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$936K

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$24.3M
2
MDVN
MEDIVATION, INC.
MDVN
+$3.11M
3
IQV icon
IQVIA
IQV
+$1.42M
4
HOLX
Hologic
HOLX
+$571K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$291K

Sector Composition

Rank Sector Weight
1 Healthcare 42.47%
2 Real Estate 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$79.1B
$43.5M 24.38%
+350,000
New +$42.5M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$28.5M 16%
+430,400
New +$26.6M
XBI icon
3
State Street SPDR S&P Biotech ETF
XBI
$10B
$8.62M 4.83%
130,000
+71,143
+121% +$4.4M
IBB icon
4
iShares Biotechnology ETF
IBB
$9.45B
$7.24M 4.06%
75,000
+21,957
+41% +$2.09M
MRK icon
5
Merck
MRK
$322B
$5.22M 2.93%
87,718
– –
BIB icon
6
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$4.12M 2.31%
+85,000
New +$4.04M
BMY icon
7
Bristol-Myers Squibb
BMY
$129B
$4.08M 2.29%
75,686
+3,983
+6% +$256K
AZN icon
8
AstraZeneca
AZN
$269B
$3.94M 2.21%
60,000
+5,718
+11% +$374K
ALKS icon
9
Alkermes
ALKS
$8.11B
$3.84M 2.15%
81,677
-1,181
-1% -$56.2K
PFE icon
10
Pfizer
PFE
$143B
$3.8M 2.13%
118,364
– –
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
$3.67M 2.06%
67,953
-6,140
-8% -$291K
BIIB icon
12
Biogen
BIIB
$30.9B
$3.35M 1.88%
10,704
+1,662
+18% +$492K
ILMN icon
13
Illumina
ILMN
$29.5B
$3.34M 1.87%
18,915
-351
-2% -$56.2K
INCY icon
14
Incyte
INCY
$25.8B
$3.27M 1.83%
34,626
-611
-2% -$51.5K
AMGN icon
15
Amgen
AMGN
$209B
$3.06M 1.71%
18,322
-297
-2% -$50.2K
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$38.3B
$3.05M 1.71%
45,064
+1,380
+3% +$97.4K
NKTR icon
17
Nektar Therapeutics
NKTR
$2.39B
$3.03M 1.7%
11,774
-128
-1% -$33K
QGENF
18
DELISTED
QIAGEN NV
QGENF
$3.03M 1.7%
110,565
+4,814
+5% +$132K
REGN icon
19
Regeneron Pharmaceuticals
REGN
$72.9B
$3.02M 1.69%
7,512
+279
+4% +$112K
MTD icon
20
Mettler-Toledo International
MTD
$28.1B
$3.02M 1.69%
7,188
– –
ALXN
21
DELISTED
Alexion Pharmaceuticals
ALXN
$3.01M 1.69%
24,571
+7,270
+42% +$936K
AGIO icon
22
Agios Pharmaceuticals
AGIO
$2.08B
$2.89M 1.62%
54,692
+11,397
+26% +$496K
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$11.9B
$2.83M 1.59%
30,639
+1,724
+6% +$162K
CELG
24
DELISTED
Celgene Corp
CELG
$2.81M 1.57%
26,859
+3,927
+17% +$425K
VRTX icon
25
Vertex Pharmaceuticals
VRTX
$123B
$2.8M 1.57%
32,141
+1,893
+6% +$179K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2016 Portfolio in Review

As of Q3 2016, Opus Point Partners Management held 53 positions worth $178M, up 72% from $104M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management deployed $62M of net new capital in Q3 2016, opening 10 new positions and adding to 20 existing holdings. Its largest new stake was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, down from 62% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was IQVIA, an estimated $1.42M trimmed.

  • Opus Point Partners Management's largest Q3 2016 buy was ProShares Ultra NASDAQ Biotechnology: 85,000 shares worth $4.12M.
  • Opus Point Partners Management added most to State Street SPDR S&P Biotech ETF in Q3 2016, an estimated $4.4M increase.
  • Opus Point Partners Management's biggest Q3 2016 reduction was IQVIA, cutting an estimated $1.42M.
  • Opus Point Partners Management fully exited iShares Russell 2000 ETF in Q3 2016, selling an estimated $24.3M.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $178M portfolio in Q3 2016.
  • Opus Point Partners Management opened 10 new positions and closed 3 in Q3 2016.
  • Opus Point Partners Management's portfolio value rose 72% quarter-over-quarter to $178M.

Based on Opus Point Partners Management's 13F filing for Q3 2016, filed 14 Nov 2016.